Purtscher retinopathy as the initial sign of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Arch Ophthalmol 2001; 119 (9): 1388–1389. Article CAS Google Scholar ...

Purtscher’s retinopathy is rare and most commonly seen after trauma, acute pancreatitis, crush-type injury, long-bone fracture, orthopedic surgery and childbirth. 2 Acute retinal signs often persist ...

Diabetic retinopathy is another condition that can cause complete loss of vision - and it's also one of the most frequently occurring. "Diabetic retinopathy is the most common cause of ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Oral APX3330 showed clinically meaningful response compared with placebo in slowing progression of diabetic retinopathy in the phase 2 ZETA-1 trial. Ocuphire Pharma’s study results were ...

The researchers did a multicentre cross-sectional screening study for diabetic retinopathy, using a complex cluster sampling design in people aged 40 years or older individuals with known ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

The screening found 16.10% or 313 novel diabetes retinopathy patients who were detected for the first time. Dr Vardhaman Kankariya, chairman, scientific committee, Maharashtra Ophthalmological ...

Diabetic retinopathy is the most common diabetic eye disease and the leading cause of vision loss and blindness in American working age adults, which affects nearly 10 million people in the US 1.

(RTTNews) - Palatin Technologies, Inc. (PTNT), a biopharmaceutical company advancing melanocortin-based therapies, shared new preclinical findings at the 2025 ARVO Annual Meeting.

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License ...